References
- Cho NH , Shaw JE , Karuranga S , et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res ClinPract . 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023
- Global picture. IDF diabetes atlas. 8th edn. Ch 3. Available from: http://www.diabetesatlas.org/index.php?option=com_attachments&task=download&id=184:IDF_Atlas_8e_CH3. Accessed 10 19 2018.
- Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Available from: http://care.diabetesjournals.org/content/diacare/early/2018/09/27/dci18-0033.full.pdf. Acessed 11 5, 2018.
- Patel DK , Sharma RT , Patel HA , Barkate HV . Teneligliptin: a review on cardio-renal safety. Int J Basic Clin Pharmacol . 2016;5:229–234. doi:10.18203/2319-2003.
- Fisman EZ , Tenenbaum A . Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol . 2015;14:129. doi:10.1186/s12933-015-0294-0 26415691
- Kishimoto M . Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndrome Obesity . 2013;6:187–195. doi:10.2147/DMSO
- Guidance for industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available from: file:///C:/Users/admin/Downloads/USFDA%20Guidance%20document-E14%20Clinical%20Evaluation%20of%20QTc.pdf. Accessed 10 19, 2018.
- Bloomfield DM , Krishna R , Hreniuk D , et al. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol . 2009;49(8):937–946. doi:10.1177/0091270009337511 19602719
- Report on the Deliberation Results. Evaluation and licensing division, pharmaceutical and food safety bureau, ministry of health, labour and welfare; 4 27, 2012 Available from: https://www.pmda.go.jp/files/000153594.pdf. Acessed 10 18, 2018.
- Halabi A , Maatouk H , Siegler KE , Faisst N , Hinrichsen H . Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharmacol Drug Dev . 2014;3(4):290–296. doi:10.1002/cpdd.89 27128835
- Singh AK . Efficacy and safety of teneligliptin. Indian J Endocrinol Metab . 2017;21(1):11–17. doi:10.4103/2230-8210.193163 28217491
- Pharmaceuticals and Medical Devices Agency (PMDA) Japan. Teneligliptin review; 2012 Available from: https://www.pmda.go.jp/files/000153594.pdf. Accessed 5 20, 2016.
- Kutoh E , Hirate M , Ikeno Y . Teneligliptin as an initial therapy for newly diagnosed, drug naïve subjects with type 2 diabetes. J Clin Med Res . 2014;6:287–294. doi:10.14740/jocmr1809w 24883155
- Ghosh S , Trivedi S , Sanyal D , Modi KD , Kharb S . Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndrome Obesity . 2016;9:347–353. doi:10.2147/DMSO.S121770
- Kadowaki T , Marubayashi F , Yokota S , Katoh M , Iijima H . Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: A pooled analysis of two phase III clinical studies. Expert Opin Pharmacother . 2015;16:971–978. doi:10.1517/14656566.2015.1032249 25861982